← Back to Search

Online Cancer Screening & HPV Vaccination Strategy for Cervical Cancer Prevention

N/A
Waitlist Available
Led By Lara Savas, PhD
Research Sponsored by The University of Texas Health Science Center, Houston
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8-month follow up
Awards & highlights
No Placebo-Only Group

Summary

This trial will develop and test an online strategy to help increase breast and cervical cancer screening and HPV vaccination rates for Latinas.

Who is the study for?
This trial is for Latinas aged 21-65 who haven't had a Pap test in the last 3 years, those aged 50-75 without a mammogram in the past 2 years, and those aged 21-26 who haven't started HPV vaccination. Participants must intend to use SEMM and be served by clinics with LHWs that cater to Latina populations in Texas.
What is being tested?
The study is testing 'Salud en Mis Manos' (SEMM), an internet platform designed to improve breast/cervical cancer screening and HPV vaccination among Latinas. It compares usual implementation practices against SEMM with extra support strategies.
What are the potential side effects?
Since this trial focuses on implementing a screening and vaccination program rather than testing new medications, it does not have typical medication side effects. However, there may be discomfort or other minor effects from the screening procedures or vaccinations.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8-month follow-up
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8-month follow-up for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Effectiveness (for HPV vaccination) as measured by the percentage of female patients who initiate or complete an HPV vaccination among all eligible patients.
Effectiveness (for screening) as measured by the percentage of women who complete cervical cancer screening (Pap or HPV screening test) among all eligible patients.
Effectiveness (for screening) as measured by the percentage of women who complete mammogram screening among all eligible patients.
+8 more
Secondary study objectives
Cost effectiveness of SEMM-DIA in community and clinic practice settings

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Salud en Mis Manos - Dissemination and Implementation AssistanceExperimental Treatment1 Intervention
The multi-component and multi-faceted implementation strategy SEMM-DIA
Group II: Salud en Mis Manos - Usual Implementation PracticeActive Control1 Intervention
The SEMM-Usual Implementation Practice arm includes all existing SEMM program materials.

Find a Location

Who is running the clinical trial?

The University of Texas Health Science Center, HoustonLead Sponsor
946 Previous Clinical Trials
342,289 Total Patients Enrolled
2 Trials studying Cancer Prevention
2,054 Patients Enrolled for Cancer Prevention
Centers for Disease Control and PreventionFED
888 Previous Clinical Trials
21,994,629 Total Patients Enrolled
Lara Savas, PhDPrincipal InvestigatorThe University of Texas Health Science Center, Houston
3 Previous Clinical Trials
16,770 Total Patients Enrolled

Media Library

Salud en Mis Manos - Dissemination and Implementation Assistance Clinical Trial Eligibility Overview. Trial Name: NCT05524480 — N/A
Cancer Prevention Research Study Groups: Salud en Mis Manos - Dissemination and Implementation Assistance, Salud en Mis Manos - Usual Implementation Practice
Cancer Prevention Clinical Trial 2023: Salud en Mis Manos - Dissemination and Implementation Assistance Highlights & Side Effects. Trial Name: NCT05524480 — N/A
Salud en Mis Manos - Dissemination and Implementation Assistance 2023 Treatment Timeline for Medical Study. Trial Name: NCT05524480 — N/A
~1143 spots leftby Nov 2025